| Catalog No. | Size | Price (USD) |
| 11049-VNAS-1 | 1 mg | $6,220.66 |
| 11049-VNAS-100 | 100 µg | $958.28 |
General Information
| Formulation | Lyophilized from sterile 25 mM Sodium Citrate，200 mM Nacl，0.02% Tween80, pH 6.0. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Endotoxin | < 1.0 EU per μg protein as determined by the LAL method. |
| Shipping | In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise. |
| Stability & Storage | Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
| Reconstitution | To find reconstitution info, click on 'COA' at the top of the page, enter the lot number and product size for the lot-specific COA. |
| Purity | ≥ 95 % as determined by SDS-PAGE. ≥ 90 % as determined by SEC-MALS. |
| Activity | 1.Immobilized Human respiratory syncytial virus (RSV) (A2) Prefusion glycoprotein F/ RSV-preF Protein(Cat:11049-VNAS) at 0.5μg/mL (100μL/well) can bind RSV specific antibody which targets antigenic site II (Palivizumab), the EC 50 is 0.5 ng/mL-1.7 ng/mL. 2.Immobilized Human respiratory syncytial virus (RSV) (A2) Prefusion glycoprotein F/ RSV-preF Protein (Cat:11049-VNAS) at 0.5μg/mL (100μL/well) can bind RSV specific antibody which targets antigenic Site Ø (Nirsevimab), the EC 50 is 0.45 ng/mL-1.35 ng/mL (Routinely tested). 3.Immobilized Human respiratory syncytial virus (RSV) (A2) Prefusion glycoprotein F/ RSV-preF Protein(Cat:11049-VNAS) at 0.5μg/mL (100μL/well) can bind prefusion specific antibody which targets antigenic Site V (Suptavumab),the EC 50 is 0.05 ng/mL-0.15 ng/mL(Routinely tested). 4.Nirsevimab-derived anti-RSV-preF antibody, Human IgG1 captured on Protein A chip, can bind Human respiratory syncytial virus (RSV) (A2) Prefusion glycoprotein F/ RSV-preF Protein (Cat. No. 11049-VNAS) with an affinity constant of 6.290 nM as determined in an SPR assay (Biacore 8K) (Routinely tested). |
| Expressed Host | CHO Cells |
| Species | RSV |
| Molecule Mass | The recombinant RSV (A2）Prefusion glycoprotein F has a predicted molecular mass of 54.5 kDa.It migrates as an approximately 57.6 kDa band in SDS-PAGE under reducing conditions. The molecular weight of this protein is around 160 kDa -190kDa verified by SEC-MALS. |
Image / Experimental Information
| Image 1 Alt Text | RSV RSV Fusion Protein 36582 |
| Image 1 URL | Source image |
| Image 2 Alt Text | RSV RSV Fusion Protein 36626 |
| Image 2 URL | Source image |
| Image 3 Alt Text | RSV RSV Fusion Protein 36627 |
| Image 3 URL | Source image |
| Image 4 Alt Text | RSV RSV Fusion Protein 36628 |
| Image 4 URL | Source image |
| Image 5 Alt Text | RSV RSV Fusion Protein 36630 |
| Image 5 URL | Source image |
Background Information
| Description | Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. It is classified within the genus pneumovirus of the family paramyxoviridae. Like other members of the family, HRSV has two major surface glycoproteins (G and F) that play important roles in the initial stages of the infectious cycle. The G protein mediates attachment of the virus to cell surface receptors, while the F protein promotes fusion of the viral and cellular membranes, allowing entry of the virus ribonucleoprotein into the cell cytoplasm. The fusion (F) protein of RSV is synthesized as a nonfusogenic precursor protein (F), which during its migration to the cell surface is activated by cleavage into the disulfide-linked F1 and F2 subunits. This fusion is pH independent and occurs directly at the outer cell membrane, and the F2 subunit was identifed as the major determinant of RSV host cell specificity. The trimer of F1-F2 interacts with glycoprotein G at the virion surface. Upon binding of G to heparan sulfate, the hydrophobic fusion peptide is unmasked and induces the fusion between host cell and virion membranes. Notably, RSV fusion protein is unique in that it is able to interact directly with heparan sulfate and therefore is sufficient for virus infection. Furthermore, the fusion protein is also able to trigger p53-dependent apoptosis. |
| References |
|
title: Immunogenicity of a Recombinant MVA Vector Vaccine Expressing the Prefusion RSV F Protein in Balb/c Mice.
authors: Jinhui Miao; Min Liu; ...; Cheng He
journal: Vaccines
date: 2026-04-27
pmid: 42042793
doi: 10.3390/vaccines14040317
cited_by_count: 0
techniques: Enzyme-linked Immunosorbent Assay; Virus
bioz_score: 94
title: Highly Efficient and Durable Th1-Biased Protective Immunity Induced by a Novel mRNA-LNP Vaccine Against RSV via AI-Assisted Antigen Screening.
authors: Kai Dong; Fang Liu; ...; Gengshen Song
journal: Molecular therapy : the journal of the American Society of Gene Therapy
date: 2026-01-28
pmid: 41612695
doi: 10.1016/j.ymthe.2026.01.031
cited_by_count: 1
techniques: Enzyme-linked Immunosorbent Assay; Expressing; Virus
bioz_score: 94
title: Genetically heterozygous - transcriptionally homozygous IRF7 deficiency underlies herpesvirus CNS infections in humans.
authors: Marvin Werner; Jonas Holst Wolff; ...; Trine H Mogensen
journal: The Journal of Experimental Medicine
date: 2025-10-29
pmid: 41159916
doi: 10.1084/jem.20250492
cited_by_count: 0
techniques: Binding Assay; Enzyme-linked Immunosorbent Assay; Neutralization; Recombinant; Serial Dilution; Virus
bioz_score: 94
title: Developing an eVLP mRNA vaccine for respiratory syncytial virus with enhanced pre-fusion targeting humoral responses
authors: Lei Sun; Mengting Huang; ...; Mark T. Heise
journal: Journal of virology
date: 2025-10-01
pmid: 41025792
doi: 10.1128/jvi.01209-25
cited_by_count: 1
techniques: Agarose Gel Electrophoresis; Binding Assay; Cell Culture; Construct; Control; Enzyme-linked Immunosorbent Assay; Expressing; Fluorescence; Immunofluorescence; In Vitro; Incubation; Labeling; Membrane; Nucleic Acid Electrophoresis; Recombinant; Standard Deviation; Transfection; Two Tailed Test; Vaccines; Western Blot
bioz_score: 94
title: Combining Intramuscular and Intranasal Immunization With the MF59‐Adjuvanted Respiratory Syncytial Virus Pre‐Fusion Protein Subunit Vaccine Induces Potent Humoral and Cellular Immune Responses in Mice
authors: Jie Shi; Hong Lei; ...; Xiawei Wei
journal: MedComm
date: 2025-07-15
pmid: 40672433
doi: 10.1002/mco2.70301
cited_by_count: 1
techniques: Adjuvant; Virus; Whisker Assay
bioz_score: 94
title: Improved mRNA-based RSV vaccine with PreF forming enveloped virus-like particles
authors: Pengdi Chai; Yi Shi; ...; Zhaojun Duan
journal: NPJ vaccines
date: 2025-07-12
pmid: 40651980
cited_by_count: 2
techniques: Binding Assay; Concentration Assay; Incubation
bioz_score: 94
title: Intranasal Inoculation of Cationic Crosslinked Carbon Dots‐Adjuvanted Respiratory Syncytial Virus F Subunit Vaccine Elicits Mucosal and Systemic Humoral and Cellular Immunity
authors: Hong Lei; Aqu Alu; ...; Yuquan Wei
journal: MedComm
date: 2025-03-24
doi: 10.1002/mco2.70146
pmcid: 11933438
cited_by_count: 1
techniques: Blocking Assay; Comparison; Enzyme-linked Immunosorbent Assay; Enzyme-linked Immunospot; Incubation; Infection; Isolation; Neutralization; Staining; Whisker Assay
bioz_score: 94
title: Epitope-focused vaccine immunogens design using tailored horseshoe-shaped scaffold.
authors: Fangxin Zhao; Yue Zhang; ...; Wei Chen
journal: Journal of Nanobiotechnology
date: 2025-02-19
pmid: 39966941
cited_by_count: 3
techniques: BIA-KA; Clone Assay; Concentration Assay; Conjugation Assay; Expressing; Purification; Sequencing
bioz_score: 94
title: Decline of Antibodies to Major Viral and Bacterial Respiratory Pathogens During the COVID-19 Pandemic
authors: Natalie Lorenz; Alex James; ...; Nicole J Moreland
journal: The Journal of Infectious Diseases
date: 2025-01-15
pmid: 39673749
pmcid: 11793024
cited_by_count: 7
techniques: Inhibition; Recombinant
bioz_score: 94
title: A bivalent mRNA vaccine against RSV infection in rodent models.
authors: Juan Liu; Hanqing Zhao; ...; Yongsheng Yang
journal: Frontiers in Immunology
date: 2024-12-10
pmid: 40196112
cited_by_count: 0
techniques: Cell Culture; Enzyme-linked Immunosorbent Assay; Enzyme-linked Immunospot; Negative Control; Neutralization; Saline; Sandwich ELISA; Vaccines; Virus
bioz_score: 94
title: Cold-adapted influenza vaccine carrying three repeats of a respiratory syncytial virus (RSV) fusion glycoprotein epitope site protects BALB/c mice and cotton rats against RSV infection.
authors: Yongru Xu; Fang Sun; ...; Penghui Yang
journal: Antiviral research
date: 2024-08-12
pmid: 38986872
doi: 10.1016/j.antiviral.2024.105960
cited_by_count: 4
techniques: Enzyme-linked Immunosorbent Assay; Incubation; Negative Control; Recombinant
bioz_score: 94
